

Wendy Stock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6391090/publications.pdf>

Version: 2024-02-01

232
papers

12,425
citations

50276

46
h-index

27406

106
g-index

234
all docs

234
docs citations

234
times ranked

12565
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2022, 53, 100908.	5.7	5
2	Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. <i>Blood</i> , 2022, 139, 2212-2226.	1.4	34
3	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	1.6	44
4	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3433-3439.	5.2	5
5	Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. <i>JCO Oncology Practice</i> , 2022, 18, 479-487.	2.9	17
6	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718.	1.6	9
7	Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4085-4092.	5.2	10
8	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	4.1	30
9	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
10	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 284-299.	13.2	70
11	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	9.4	137
12	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.	12.8	103
13	OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 48.	6.2	5
14	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
15	Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021, 2, 413-420.	1.0	4
16	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.20.01739.	1.6	10
17	Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2846-2867.	9.4	83
18	SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 725-733.	0.4	11

#	ARTICLE	IF	CITATIONS
19	The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. <i>Blood</i> , 2021, 138, 1870-1884.	1.4	20
20	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , 2021, 81, 3833-3847.e11.	9.7	10
21	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , 2021, 5, 4691-4700.	5.2	9
22	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
23	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study). <i>Blood</i> , 2021, 138, 2344-2344.	1.4	1
24	Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 614-622.	1.3	29
25	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2020, 10, CD013399.	2.8	6
26	Thrombosis in ALL: a risk without clear mitigation. <i>Blood</i> , 2020, 136, 264-265.	1.4	2
27	New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 424-435.	2.3	3
28	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
29	Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. <i>Current Treatment Options in Oncology</i> , 2020, 21, 57.	3.0	24
30	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. <i>Leukemia Research</i> , 2020, 95, 106385.	0.8	26
31	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	2.4	11
32	Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. <i>Lancet Oncology</i> , 2020, 21, 421-435.	10.7	167
33	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 449-457.	5.2	37
34	A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 937-943.	4.1	3
35	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	5.2	44
36	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 599-606.	5.2	9

#	ARTICLE	IF	CITATIONS
37	Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study. <i>Blood</i> , 2020, 136, 4-5.	1.4	52
38	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. <i>Blood</i> , 2020, 136, 41-42.	1.4	2
39	Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2020, 136, 27-30.	1.4	3
40	Philadelphia Chromosome-“Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>JCO Oncology Practice</i> , 2020, 16, 231-238.	2.9	4
41	Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
42	The Role of Structural Violence in Acute Myeloid Leukemia Outcomes. <i>Blood</i> , 2020, 136, 10-10.	1.4	2
43	D-Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
44	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). <i>Blood</i> , 2020, 136, 39-40.	1.4	0
45	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 629-638.	1.3	4
46	Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224097.	2.5	17
47	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
48	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
49	Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 431-440.e13.	0.4	46
50	Taking a “BiTE out of ALL” blinatumomab approval for MRD-positive ALL. <i>Blood</i> , 2019, 133, 1715-1719.	1.4	39
51	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.	5.2	25
52	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019, 3, 3488-3498.	5.2	62
53	Philadelphia chromosome-like acute lymphocytic leukemia: Perspectives on diagnosis. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e69.	0.9	2
54	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2019, , .	2.8	2

#	ARTICLE	IF	CITATIONS
55	Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27542.	1.5	14
56	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	1.4	292
57	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. <i>American Journal of Hematology</i> , 2019, 94, 408-416.	4.1	11
58	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	21.4	384
59	Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. <i>Blood</i> , 2019, 134, 1344-1344.	1.4	3
60	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. <i>Blood</i> , 2019, 134, 4176-4176.	1.4	3
61	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1956-1956.	1.4	2
62	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	1.4	24
63	CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2630-2630.	1.4	4
64	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	1.4	5
65	Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response. <i>Blood</i> , 2019, 134, 3846-3846.	1.4	2
66	Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. <i>Blood</i> , 2019, 134, 2957-2957.	1.4	3
67	Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. <i>Blood</i> , 2019, 134, 175-175.	1.4	8
68	Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial. <i>Blood</i> , 2019, 134, 2145-2145.	1.4	1
69	Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial. <i>Blood</i> , 2019, 134, 373-373.	1.4	2
70	Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7029-7029.	1.6	0
71	Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients. <i>Blood</i> , 2019, 134, 1319-1319.	1.4	0
72	Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML. <i>Blood</i> , 2019, 134, 3413-3413.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. <i>Blood</i> , 2019, 134, 3324-3324.	1.4	0
74	The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression. <i>Blood</i> , 2019, 134, 2748-2748.	1.4	0
75	Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	14
76	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-â€“Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 725.	7.1	111
77	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INOâ€“VATE. <i>Cancer</i> , 2018, 124, 1722-1732.	4.1	43
78	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 997-1004.	2.0	18
79	Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 299-308.	0.9	38
80	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
81	Should immunologic strategies be incorporated into frontline ALL therapy?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 367-372.	1.7	2
82	Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 636-647.	0.4	6
83	Acute Lymphoblastic Leukemia in Adults. , 2018, , 1029-1054.e2.		2
84	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 4.	17.0	52
85	WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2018, 7, 1.	5.0	24
86	Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018, 132, 231-231.	1.4	4
87	Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials. <i>Blood</i> , 2018, 132, 2699-2699.	1.4	5
88	A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1397-1397.	1.4	3
89	Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine,) Tj ETQq1 1 0.784314 rgBT /Ov Chromosome Negative B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 33-33.	1.4	37
90	TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases. <i>Blood</i> , 2018, 132, 2984-2984.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. <i>Blood</i> , 2018, 132, 2245-2245.	1.4	1
92	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). <i>Blood</i> , 2018, 132, 146-146.	1.4	6
93	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2018, 132, 3966-3966.	1.4	5
94	Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2246-2246.	1.4	4
95	Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 3415-3415.	1.4	11
96	Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial. <i>Blood</i> , 2018, 132, 287-287.	1.4	13
97	Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies. <i>Blood</i> , 2018, 132, 559-559.	1.4	14
98	Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase I Study. <i>Blood</i> , 2018, 132, 763-763.	1.4	43
99	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701. <i>Blood</i> , 2018, 132, 309-309.	1.4	14
100	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	1.4	14
101	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , 2018, 132, 2767-2767.	1.4	0
102	Evaluation of Romylocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy. <i>Blood</i> , 2018, 132, 1407-1407.	1.4	1
103	Higher Socioeconomic Status Is Associated with Improved Overall Survival in Adults with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: A Population Study. <i>Blood</i> , 2018, 132, 4780-4780.	1.4	1
104	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 4073-4073.	1.4	0
105	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2127-2133.	1.3	20
106	Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 312-320.	2.5	75
107	High Frequency and Poor Outcome of Philadelphia Chromosome-“Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017, 35, 394-401.	1.6	326
108	De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. <i>Chest</i> , 2017, 152, 683-685.	0.8	12

#	ARTICLE	IF	CITATIONS
109	Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). <i>Leukemia and Lymphoma</i> , 2017, 58, 950-958.	1.3	18
110	Acute Lymphoblastic Leukemia. <i>Pediatric Oncology</i> , 2017, , 151-175.	0.5	3
111	Adoption of pediatricâ€inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A populationâ€based study. <i>Cancer</i> , 2017, 123, 122-130.	4.1	38
112	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. <i>Blood Advances</i> , 2017, 1, 1167-1180.	5.2	103
113	Progress in adult ALL: incorporation of new agents to frontline treatment. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 28-36.	2.5	15
114	Psychological morbidities in adolescent and young adult blood cancer patients during curativeâ€intent therapy and early survivorship. <i>Cancer</i> , 2016, 122, 954-961.	4.1	60
115	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. <i>Haematologica</i> , 2016, 101, 634-643.	3.5	30
116	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	27.0	663
117	The Persistence of Minimal Residual Disease in Philadelphia Chromosomeâ€Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1913-1914.	2.0	5
118	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	12.8	218
119	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	21.4	231
120	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1065-1072.	2.0	20
121	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	27.0	1,047
122	Incorporating measurable (â€minimalâ€™) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1527-1533.	1.3	7
123	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. <i>Leukemia and Lymphoma</i> , 2016, 57, 1807-1813.	1.3	9
124	Clinical impact of <i>ABL1</i> kinase domain mutations and <i>IKZF1</i> deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. <i>Leukemia and Lymphoma</i> , 2016, 57, 2298-2306.	1.3	45
125	WT1 Peptide Vaccine Is Able to Induce WT1-Specific Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3984-3984.	1.4	1
126	Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. <i>Oncotarget</i> , 2016, 7, 68833-68841.	1.8	67

#	ARTICLE	IF	CITATIONS
127	Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. Journal of Clinical Oncology, 2016, 34, e18537-e18537.	1.6	0
128	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
129	Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Translational Oncology, 2015, 8, 368-375.	3.7	19
130	T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget, 2015, 6, 33410-33425.	1.8	22
131	Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives. Current Hematologic Malignancy Reports, 2015, 10, 132-144.	2.3	31
132	How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood, 2015, 125, 3702-3710.	1.4	121
133	Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leukemia Research, 2015, 39, 1437-1442.	0.8	11
134	Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population. Blood, 2015, 126, 1291-1291.	1.4	3
135	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. Blood, 2015, 126, 2618-2618.	1.4	5
136	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	1.4	23
137	A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL). Blood, 2015, 126, 4866-4866.	1.4	1
138	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	1.4	1
139	Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2518-2518.	1.4	3
140	Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 2491-2491.	1.4	14
141	Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3777-3777.	1.4	0
142	Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica, 2014, 99, 111-115.	3.5	94
143	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leukemia and Lymphoma, 2014, 55, 1523-1532.	1.3	55
144	A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenetics and Genomics, 2014, 24, 129-132.	1.5	10

#	ARTICLE	IF	CITATIONS
145	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 652-665.	16.8	274
146	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	27.0	1,161
147	Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. <i>Leukemia Research</i> , 2014, 38, 1091-1096.	0.8	17
148	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.	3.5	213
149	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. <i>Blood</i> , 2014, 124, 1093-1093.	1.4	4
150	A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. <i>Blood</i> , 2014, 124, 2255-2255.	1.4	18
151	Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance). <i>Blood</i> , 2014, 124, 2301-2301.	1.4	1
152	First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2014, 124, 529-529.	1.4	4
153	Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014, 124, 796-796.	1.4	83
154	Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). <i>Blood</i> , 2014, 124, 8-8.	1.4	31
155	Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. <i>Oncotarget</i> , 2014, 5, 12371-12382.	1.8	56
156	Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2463-2463.	1.4	0
157	Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA). <i>Blood</i> , 2014, 124, 2464-2464.	1.4	0
158	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. <i>Blood</i> , 2014, 124, 2509-2509.	1.4	2
159	A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance). <i>Blood</i> , 2014, 124, 2306-2306.	1.4	1
160	Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 90-98.	4.1	104
161	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 676-683.	1.6	171
162	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. <i>Blood</i> , 2013, 122, 1548-1548.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance). <i>Blood</i> , 2013, 122, 2547-2547.	1.4	1
164	Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). <i>Blood</i> , 2013, 122, 2653-2653.	1.4	3
165	Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). <i>Blood</i> , 2013, 122, 3002-3002.	1.4	2
166	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	1.4	35
167	Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3906-3906.	1.4	9
168	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.	1.4	23
169	Suffering Before The Cure: Evaluation Of Psychological Morbidities In Adolescents and Young Adults With Hematologic Malignancies In Early Survivorship. <i>Blood</i> , 2013, 122, 771-771.	1.4	1
170	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013, 122, 825-825.	1.4	8
171	Growth Inhibitory Function Of a Novel T-LAK Cell-Originated Protein Kinase Inhibitor On FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cells. <i>Blood</i> , 2013, 122, 1459-1459.	1.4	0
172	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1398-1398.	1.4	0
173	Treatment-influenced associations of PML-RAR \pm mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. <i>Blood</i> , 2012, 120, 2098-2108.	1.4	52
174	Children, Adolescents, and Young Adults With Leukemia: The Empty Half of the Glass Is Growing. <i>Journal of Clinical Oncology</i> , 2012, 30, 4037-4038.	1.6	17
175	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). <i>Leukemia and Lymphoma</i> , 2012, 53, 445-450.	1.3	20
176	FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2012, 59, 662-667.	1.5	48
177	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 3535-3535.	1.4	1
178	Results From the Dose Escalation Phase of a Randomized Phase 1â€“2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. <i>Blood</i> , 2012, 120, 414-414.	1.4	11
179	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). <i>Blood</i> , 2012, 120, 44-44.	1.4	4
180	Treating the younger adult with acute lymphoblastic leukemia. <i>Clinical Practice (London, England)</i> , 2012, 9, 439-449.	0.1	4

#	ARTICLE	IF	CITATIONS
181	Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo® (vinCRISTine sulfate LIPOSOME injection). <i>Blood</i> , 2012, 120, 4805-4805.	1.4	0
182	Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 107-108.	1.3	13
183	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011, 118, 6438-6445.	1.4	158
184	Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leukemia and Lymphoma</i> , 2011, 52, 2237-2253.	1.3	198
185	High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. <i>Leukemia Research</i> , 2011, 35, 329-333.	0.8	27
186	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011, 118, 258-258.	1.4	7
187	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. <i>Blood</i> , 2011, 118, 1948-1948.	1.4	0
188	Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. <i>Blood</i> , 2011, 118, 2541-2541.	1.4	3
189	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. <i>Blood</i> , 2011, 118, 830-830.	1.4	1
190	A Phase II Prospective Feasibility Study of Clofarabine Cyto-reduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 496-496.	1.4	0
191	P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.	1.4	113
192	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010, 116, 3751-3757.	1.4	348
193	Adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 1165-1176.	4.1	225
194	Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 21-29.	2.5	100
195	Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 188-198.	1.3	21
196	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 995-1006.	1.3	16
197	Treatment of acute lymphoblastic leukemia (ALL) in adults. , 2010, , 43-67.		0
198	Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2009, 115, 5490-5498.	4.1	57

#	ARTICLE	IF	CITATIONS
199	A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 859-864.	2.3	30
200	Looking Toward the Future: Novel Strategies Based on Molecular Pathogenesis of Acute Lymphoblastic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1099-1119.	2.2	3
201	Response: Disparity in outcome of young adults with ALL. <i>Blood</i> , 2009, 113, 1862-1862.	1.4	12
202	Pediatric regimens for adult acute lymphoblastic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 244-6.	0.3	0
203	A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. <i>Investigational New Drugs</i> , 2008, 26, 331-338.	2.6	12
204	Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 144-151.	2.3	2
205	Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 7095-7101.	7.0	67
206	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. <i>Leukemia and Lymphoma</i> , 2008, 49, 531-537.	1.3	11
207	What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. <i>Blood</i> , 2008, 112, 1646-1654.	1.4	479
208	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. <i>Blood</i> , 2008, 112, 2809-2809.	1.4	18
209	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. <i>Blood</i> , 2008, 112, 3015-3015.	1.4	1
210	Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 487-8.	0.3	4
211	Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS.. <i>Blood</i> , 2007, 110, 1076-1076.	1.4	2
212	Anti-Angiogenic Effects of Sorafenib in Relapsed Chronic Lymphocytic Leukemia: Correlative Studies of a Phase 2 Clinical Trial.. <i>Blood</i> , 2007, 110, 4726-4726.	1.4	1
213	Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.. <i>Blood</i> , 2007, 110, 1973-1973.	1.4	0
214	Unrelated Donor (URD) Searches in African-Americans with Hematologic Malignancies: Paucity of HLA Identical Donors.. <i>Blood</i> , 2007, 110, 5064-5064.	1.4	0
215	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	1.4	1,117
216	Controversies in Treatment of AML: Case-based Discussion. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 185-191.	2.5	7

#	ARTICLE	IF	CITATIONS
217	Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2794-2799.	7.1	525
218	Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2006, 108, 4539-4539.	1.4	0
219	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1952-1952.	1.4	0
220	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	1.4	0
221	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology, 2006, 28, 1099-103.	3.3	10
222	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. Journal of Clinical Oncology, 2005, 23, 3404-3411.	1.6	143
223	Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. Blood, 2005, 106, 1833-1833.	1.4	5
224	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	1.4	1
225	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. Blood, 2005, 106, 1818-1818.	1.4	0
226	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	1.4	11
227	The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 264-264.	1.4	10
228	Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 865-865.	1.4	15
229	A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. Blood, 2004, 104, 873-873.	1.4	5
230	CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the philadelphia chromosome. Genes Chromosomes and Cancer, 1994, 9, 141-144.	2.8	4
231	Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. Leukemia and Lymphoma, 1991, 4, 145-148.	1.3	1
232	Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. Journal of Assisted Reproduction and Genetics, 0, , .	2.5	2